Neoleukin Therapeutics (NLTX) Competitors $11.49 +0.72 (+6.69%) As of 04/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NLTX vs. PGEN, STOK, SANA, UPB, PRTC, SION, RVNC, ABVX, ZVRA, and HCWBShould you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Precigen (PGEN), Stoke Therapeutics (STOK), Sana Biotechnology (SANA), Upstream Bio (UPB), PureTech Health (PRTC), Sionna Therapeutics (SION), Revance Therapeutics (RVNC), ABIVAX Société Anonyme (ABVX), Zevra Therapeutics (ZVRA), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical products" industry. Neoleukin Therapeutics vs. Precigen Stoke Therapeutics Sana Biotechnology Upstream Bio PureTech Health Sionna Therapeutics Revance Therapeutics ABIVAX Société Anonyme Zevra Therapeutics HCW Biologics Precigen (NASDAQ:PGEN) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment. Which has higher earnings & valuation, PGEN or NLTX? Neoleukin Therapeutics has lower revenue, but higher earnings than Precigen. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecigen$3.93M104.13-$95.90M-$0.48-2.90Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-3.69 Does the MarketBeat Community favor PGEN or NLTX? Precigen received 387 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 67.44% of users gave Precigen an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformPrecigenOutperform Votes43767.44% Underperform Votes21132.56% Neoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% Which has more volatility and risk, PGEN or NLTX? Precigen has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Is PGEN or NLTX more profitable? Neoleukin Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -3,521.68%. Neoleukin Therapeutics' return on equity of -37.22% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Precigen-3,521.68% -123.06% -87.33% Neoleukin Therapeutics N/A -37.22%-30.91% Do insiders & institutionals believe in PGEN or NLTX? 33.5% of Precigen shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 44.9% of Precigen shares are held by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor PGEN or NLTX? In the previous week, Precigen had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Precigen and 0 mentions for Neoleukin Therapeutics. Precigen's average media sentiment score of 0.00 equaled Neoleukin Therapeutics'average media sentiment score. Company Overall Sentiment Precigen Neutral Neoleukin Therapeutics Neutral Do analysts prefer PGEN or NLTX? Precigen presently has a consensus price target of $7.00, suggesting a potential upside of 403.60%. Given Precigen's stronger consensus rating and higher possible upside, equities analysts plainly believe Precigen is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precigen 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryPrecigen beats Neoleukin Therapeutics on 11 of the 16 factors compared between the two stocks. Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLTX vs. The Competition Export to ExcelMetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$107.98M$6.44B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-3.696.8921.8617.80Price / SalesN/A230.57380.5497.75Price / CashN/A65.6738.2634.64Price / Book1.045.936.453.98Net Income-$57.56M$142.99M$3.22B$247.81M7 Day Performance28.09%4.43%2.85%1.80%1 Month Performance-31.89%-12.72%-8.67%-6.81%1 Year Performance-63.62%-9.42%11.46%1.31% Neoleukin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLTXNeoleukin TherapeuticsN/A$11.49+6.7%N/A-69.4%$107.98MN/A-3.6990High Trading VolumePGENPrecigen3.1714 of 5 stars$1.40flat$7.00+400.0%+6.1%$411.66M$3.93M-2.55190STOKStoke Therapeutics3.3718 of 5 stars$7.56+7.7%$24.67+226.3%-34.4%$408.83M$36.56M-3.60100Analyst RevisionSANASana Biotechnology2.3094 of 5 stars$1.81+2.8%$10.80+496.7%-80.0%$407.30MN/A-1.29380UPBUpstream BioN/A$7.58+2.8%$56.50+645.4%N/A$406.60M$2.37M0.0038Positive NewsPRTCPureTech Health3.0681 of 5 stars$16.68+3.2%$45.00+169.8%-37.1%$400.64M$3.33M0.00100Upcoming EarningsShort Interest ↓Positive NewsSIONSionna TherapeuticsN/A$8.91+13.2%$38.50+332.1%N/A$393.15MN/A0.0035Gap DownRVNCRevance Therapeutics2.0863 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500ABVXABIVAX Société Anonyme2.1266 of 5 stars$6.00+0.5%$38.00+533.3%-57.0%$380.51MN/A0.0061Short Interest ↑Gap DownZVRAZevra Therapeutics2.5418 of 5 stars$6.98+1.2%$22.29+219.3%+54.1%$377.73M$23.61M-3.5420News CoveragePositive NewsHCWBHCW BiologicsN/A$8.29-9.7%N/A-88.9%$372.50M$2.57M-8.2940Gap Down Related Companies and Tools Related Companies Precigen Alternatives Stoke Therapeutics Alternatives Sana Biotechnology Alternatives Upstream Bio Alternatives PureTech Health Alternatives Sionna Therapeutics Alternatives Revance Therapeutics Alternatives ABIVAX Société Anonyme Alternatives Zevra Therapeutics Alternatives HCW Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLTX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NLTX Stock Free NLTX Stock Alerts